GHP Q3 2019

GHP / Q3 2019 5 NEWS , C l e a r C o u r s e Partnership LLP (“ClearCourse” or “the Partnership”), a group of innovative technology companies provid- ing software, services and digital capabilities to the membership, events & bookings and sports & leisure sectors, announced the acquisition of e-clinic (“the Com- pany”), a leading patient and clin- ic management software provider. The deal is ClearCourse’s 13th since its foundation in October 2018 and represents an expan- sion of Partnership’s product of- fering into the healthcare industry. e-clinic was founded in 2002 and continues to operate from its headquarters in Shipley, West Yorkshire, where it employs 7 peo- ple. Its intuitive proprietary cloud- based software package, ‘e-clinic 2’ is used by clients around the world, from small private medical practices to multi-site, multi-dis- ciplinary clinics and hospitals, in- cluding the Harley Medical Group, Courthouse Clinics, and EF Me- dispa. e-clinic helps its clients streamline operations through workload automation and work- flow management. The Company has consistently led innovation in clinic administration, having been the first to implement many fea- tures now ubiquitous in the indus- try such as text message booking systems, digital clinical document annotation, patient marketing, multi-layered diaries and integrat- ed card payments. e-clinic offers clients training and support ser- vices, as well as an in-house de- velopment team that is on hand to tailor the platform to meet their individual requirements. ClearCourse was established to add value in innovative, well performing UK-based technology companies that provide digital services, including payment ca- pabilities, to membership, events and bookings organsations. ClearCourse will work closely with e-clinic’s senior team, pro- viding operational expertise and financial resources to bolster and support the Company’s ambitious growth strategy and continued platform development. e-clinic will also gain access to improved payments infrastructure and oth- Orion Biotechnol- ogy Canada Ltd. announced that the Polish National Reg- ulatory Agency and Local Ethics Committee have giv- en approval for the OB-002H-101 Phase 1 safety and acceptability study of OB-002H gel to start screening and enrollment. The OB-002H gel is a topical formula- tion of OB-002 (5P12-RANTES), a novel chemokine analogue that binds to the CCR5 receptors in or- der to prevent HIV infection. OB- 002 is best-in-class in terms of in vitro potency and has previously been shown to completely pre- vent SHIV infection in a non-hu- man primate (NHP) model of HIV infection (Veazey R et al. Journal of Infectious Diseases 2009). The OB-002H-101 study will enroll 30 healthy volunteers who will receive either single or multiple vaginal or rectal doses of the gel product. The study will evalu- ate the safety, acceptability, and pharmacokinetic (PK) profile of the gel and will be conducted at a Phase 1 research unit in Warsaw, Poland. Preliminary data from the study are anticipated in Q2 2020. “Orion Biotechnology is very ex- cited to move our OB-002H gel Orion Biotechnology to Initiate Clinical Trials of Its Innovative Microbicide Gel for HIV Prevention into the clinic,” said Dr. Ian Mc- Gowan, Chief Medical Officer for Orion Biotechnology. “Despite in- creasing access to oral pre-expo- sure prophylaxis with Truvada®, we believe there is an important role for HIV prevention products that can be used in a pericoital fashion.” Mark Groper, President and CEO of Orion Biotechnology added; “It is unacceptable that we are still seeing 1.8 million new HIV infections each year and there is a compelling need to expand the HIV prevention portfolio so that men and women have more op- tions to protect themselves from HIV infection. OB-002 has been shown to be safe and 100% pro- tective in an NHP challenge mod- el which makes it an ideal micro- bicide candidate.” Professor Gita Ramjee from the Aurum Institute, Johannesburg, South Africa and a member of the OB-002H-101 Safety Monitoring Committee commented; “Young women in South Africa need more HIV prevention options and I look forward to working with the team at Orion Biotechnology to eval- uate results from their Phase 1 study of the OB-002H gel.” er technology products, including data validation services, from within the Partnership. Gerry Gualtieri, CEO of ClearCourse, commented: “e-clin- ic is a dynamic new addition to ClearCourse Partnership. The Company has developed a strong reputation in the healthcare sector for delivering first-class manage- ment solutions to an impressive list of clients around the world. We see great opportunity for commer- cial synergies between e-clinic and the wider Partnership, par- ticularly around the provision of payments and membership man- agement tools. We’re excited to work closely with the team to re- alise those synergies and support the Company’s continued growth and development.” Mark Lainchbury, Managing Di- rector of e-clinic, added: “We’re very proud to have built e-clinic into the highly successful, mar- ket-leading business that it is to- day. By joining the ClearCourse Partnership, we have access to a valuable range of resources and operational expertise that will allow us to continue to grow, develop and realise our ambitious plans for the future. We remain dedicated to creating the best possible product for our clients so that we can continue to improve patient care around the world.” The financial terms of the deal are undisclosed.